TABLE 1.

Baseline demographic and clinical characteristics of the intention-to-treat population

	Placebo N = 111	E10 N = 118	L10 N = 116	E20 N = 111	L20 N = 109	L10 + E10 N = 116	L10 + E20 N = 118	L20 + E10 N = 110	L20 + E20 N = 116	Overall N = 1025
Males (%)	50.5	47.5	44.8	48.6	44.0	49.1	52.5	48.2	45.7	47.9
Age (years)	54.7 ± 9.8	54.8 ± 9.9	53.6 ± 9.8	52.1 ± 9.4	55.4 ± 9.7	54.0 ± 10.2	53.0 ± 10.1	51.9 ± 10.2	55.8 ± 10.1	53.9 ± 9.10
White (%)	99.1	99.2	99.1	99.1	100	100	99.2	100	99.1	99.4
BMI (kg/m2)	29.89 ± 4.9	29.34 ± 5.2	30.60 ± 4.9	30.12 ± 5.2	29.73 ± 4.8	30.38 ± 4.8	29.72 ± 4.8	29.86 ± 4.7	29.11 ± 5.3	29.86 ± 4.10
Office SBP (mmHg)	160.5 ± 10.5	158.8 ± 10.3	159.5 ± 10.4	159.9 ± 9.7	159.2 ± 10.7	159.1 ± 10.2	159.4 ± 10.5	158.6 ± 10.4	159.0 ± 10.7	159.3 ± 10.4
Office DBP (mmHg)	103.2 ± 2.4	103.2 ± 2.2	102.9 ± 2.5	103.1 ± 2.6	103.3 ± 2.8	103.0 ± 2.6	102.9 ± 3.4	102.8 ± 3.1	103.1 ± 3.10	103.1 ± 2.9
Office HR (b/min)	77.6 ± 10.8	77.3 ± 11.0	77.8 ± 9.3	77.9 ± 10.6	78.5 ± 9.9	79.4 ± 9.5	78.7 ± 11.7	78.4 ± 11.3	77.1 ± 9.9	78.1 ± 10.5

Data are shown as % or as mean ± standard deviation (SD). E, enalapril; HR, heart rate; ITT, intention to treat; L, lercanidipine.